MPS Q1 FY27 earnings call

MPS Limited reported its strongest first quarter in history for Q1 FY27, with revenue reaching INR 224.24 crores, a 20.4% increase year-over-year. EBITDA surged by 53.0% to INR 76.96 crores, leading to a significant expansion in EBITDA margin to 34.3% from 27.0% in the prior year. Profit after tax grew 43.0% to INR 50.39 crores, and basic EPS hit an all-time Q1 high of INR 29.70, up from INR 20.78.

The company demonstrated strong operating leverage, with revenue growth of 20% and EBITDA growth of 53% achieved while headcount rose less than 3%. This performance resulted in a 'Rule of 50' score of 54% (20% revenue growth + 34% EBITDA margin), comfortably exceeding the 50% threshold. Management views this as evidence of a compounding business model and aims to maintain this for the full FY27.

The Research Solutions segment, comprising 55% of total revenue, grew 13.2% YoY to INR 123.23 crores, with EBITDA up 37.9% and a segment margin of 45.1%. The Education segment saw robust growth, with revenue increasing 42.2% YoY to INR 73.41 crores and achieving a 35.1% EBITDA margin. Corporate Learning, after a period of restructuring, turned a corner with 6.9% YoY revenue growth to INR 27.60 crores and a substantial 60.7% increase in EBITDA, expanding its margin to 25.3% from under 17% a year ago.

MPS is actively shifting its revenue model from effort-based to outcomes-based, where payment is tied to results like accepted manuscripts or successful learning outcomes. This shift is a key driver for margin expansion, as outcomes carry better economics. The company emphasizes its AI-first approach, with AI embedded in production workflows and product layers. Management views AI as a tailwind, particularly in high-stakes content where accuracy is critical, positioning MPS at a layer where AI cannot afford to be wrong, thus creating a structural moat.

The Unbound Medicine acquisition, now in its first full quarter, has proven its strategic thesis by providing a recurring, high-renewal subscription business in medicine and nursing. This acquisition reduces customer concentration and offers predictable revenue. Unbound Medicine currently has a monthly run rate of $800,000 and margins of 18-20%. Management expects it to reach a 'Rule of 40' (mid-20s to late 20s EBITDA margin) and eventually 'Rule of 50' as it integrates further into MPS.

MPS has refined its M&A strategy, moving away from acquiring distressed assets to focusing on businesses with inherent strength, a CAGR of at least 10% over three years, and EBITDA between 5% and 15%. The primary focus for acquisitions is in the Education sector and subject matters where AI acts as a multiplier. Rahul Arora confirmed an active pipeline, targeting assets with over $15 million in revenue, and highlighted that cultural alignment is a critical factor, citing a recent instance where a deal was abandoned due to misalignment.

The company reaffirmed its FY27 guidance to comfortably cross INR 300 crores in EBITDA, stating this as a floor rather than a ceiling. For FY28, the targets are approximately INR 1,500 crores in revenue and INR 450 crores in EBITDA. Management expressed high conviction in these targets, attributing it to the strong Q1 performance, expanded margins across all segments, and the operational model that is already in flight.